Launch of canine atopic dermatitis program and general dermatology clinical development update
Key highlights
• BTX 1204A proof of concept canine study for atopic dermatitis is underway, following encouraging data from the pilot study in Q2 CY2021
• Study will establish potential for higher dose Permetrex™ formulation in treating disease, and inform potential licensing in animal health and relaunch of late-stage clinical program in humans
• Recruitment for BTX 1702 Phase 1b rosacea study remains on track despite COVID-19 restrictions
